NEW YORK, May 24, 2011 /PRNewswire/ — Reportlinker.com
announces that a new market research report is available in its
catalogue:
Triple Analysis: Leukemia, Lymphoma and Peptides
http://www.reportlinker.com/p0284621/Triple-Analysis-Leukemia-Lymphoma-and-Peptides.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology
This triple analysis focuses on cancer drug development
strategies in both Leukemia and Lymphoma and by the compound
strategy of Peptides. Each of these three individual parts is
evaluated according to standardized criteria in a five pillar
pipeline drug assessment methodology to compare drug development
strategies in oncology. This makes it easy to find and compare
analysis not only within one single cancer focus area but also
between different areas.
Below is a short synopsis of each part included in this
report:
Part I: Leukemia
The leukemia report part comprises defined and up to date
development strategies for 313 leukemia drugs within the portfolio
of 186 investigators, from Ceased to Marketed. This part
extensively analyses their 204 identified drug targets, organized
into 193 drug target strategies, and assesses them in eight
different compound strategies and eight subindications of
leukemia.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Leukemia Pipeline:
From Research and Development to Market
Part II: Lymphoma
The lymphoma report part comprises defined and up to date
development strategies for 282 lymphoma drugs within the portfolio
of 154 investigators, from Ceased to
‘/>”/>
SOURCE